

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

PROFIT WARNING

This announcement is made by China Pioneer Pharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review on the management accounts of the Group for the year ended 31 December 2015 (“**Year 2015**”) and the information currently available to the Board, the Group is expected to record a decrease in profit for Year 2015 as compared with that reported for the year ended 31 December 2014 (“**Year 2014**”). Such decrease in profit for Year 2015 was mainly attributable to:

- (a) the operation loss of the overseas associates of the Company for Year 2015;
- (b) the substantial decrease of the sales of WaveLight Eagle laser surgical series, one of the Group’s medical device products, in Year 2015; and
- (c) the increase in the Group’s financing cost for the borrowings denominated in foreign exchange due to the depreciation of Renminbi during the second half of Year 2015.

Moreover, the management of the Company is evaluating and considering whether to make any impairment of investments in overseas associates and the amount thereof. Any such impairment will further affect the profit of the Group for Year 2015.

The Company is still in the process of finalising its audited consolidated financial statements for Year 2015. The information contained in this announcement is only based on a preliminary assessment made by the Board with reference to the information currently available, which has not been reviewed or audited by the auditors of the Company and may be subject to change. Shareholders and potential investors are advised to refer to the details of the Group's financial results for Year 2015, which are expected to be published in March 2016.

By order of the Board
China Pioneer Pharma Holdings Limited
Li Xinzhou
Chairman

Hong Kong, 24 February 2016

As at the date of this announcement, the Directors of the Company are Mr. LI Xinzhou, Mr. WANG Yinping and Mr. ZHU Mengjun as executive Directors, Mr. WU Mijia as non-executive Director and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive Directors.